Boston Scientific — Feb 4, 2026 release

BOSTON SCIENTIFIC CORPORATION Q1 and FY 2026 GUIDANCE RECONCILIATIONS (Unaudited) Net Sales Q1 2026 Estimate Full Year 2026 Estimate (Low) (High) (Low) (High) Reported growth 10.5   % 12.0   % 10.5   % 11.5   % Impact of foreign currency fluctuations (2.0) % (2.0) % (0.5) % (0.5) % Operational growth 8.5   % 10.0   % 10.0   % 11.0   % Impact of certain acquisitions/divestitures —  % —  % —  % —  % Organic growth 8.5   % 10.0   % 10.0   % 11.0   % Use of Non-GAAP Financial Measures To supplement our unaudited consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss), adjusted net income (loss) attributable to Boston Scientific common stockholders and adjusted net income (loss) per share (EPS) that exclude certain charges (credits); operational net sales, which exclude the impact of foreign currency fluctuations; and organic net sales, which exclude the impact of foreign currency fluctuations as well as the impact of certain acquisitions and divestitures with less than a full period of comparable net sales. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, wh